Kodani, Eitaro http://orcid.org/0000-0002-4271-3186
Inoue, Hiroshi
Atarashi, Hirotsugu
Okumura, Ken
Yamashita, Takeshi
Origasa, Hideki
,
Clinical trials referenced in this document:
Documents that mention this clinical trial
Impact of Body Mass Index on the Prognosis of Japanese Patients With Non-Valvular Atrial Fibrillation
https://doi.org/10.1016/j.amjcard.2016.04.036
Impact of Gender on the Prognosis of Patients With Nonvalvular Atrial Fibrillation
https://doi.org/10.1016/j.amjcard.2013.11.057
Characteristics and outcomes in elderly patients with non-valvular atrial fibrillation and high bleeding risk: subanalysis of the J-RHYTHM Registry
https://doi.org/10.1007/s00380-023-02343-9
Funding for this research was provided by:
Japan Heart Foundation (12080025)
Article History
Received: 28 August 2023
Accepted: 16 November 2023
First Online: 16 December 2023
Declarations
:
: Dr. Kodani received remuneration from Daiichi-Sankyo; Dr. Inoue received remuneration from Daiichi-Sankyo; Dr. Atarashi received remuneration from Daiichi-Sankyo; Dr. Okumura received remuneration from Boehringer Ingelheim, Bristol-Myers Squibb, Daiichi-Sankyo, Johnson & Johnson, and Medtronic; and Dr. Yamashita received research funding from Bayer Healthcare, Bristol-Meyers Squibb, and Daiichi-Sankyo and remuneration from Bayer Healthcare, Bristol-Myers Squibb, Daiichi-Sankyo, Novartis, Ono Pharmaceutical, Otsuka Pharmaceutical, and Toa Eiyo. Dr. Origasa received remuneration from Johnson & Johnson. The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.